USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PROTEOTECH, INC.
City: KIRKLAND
State: WA
Zip+4: 98034-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,646,792.00 11
SBIR Phase II $7,164,885.00 5

Award List:

PROTEOGLYCAN SPLICING IN AD--THERAPEUTICS & DIAGNOSTICS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jacques Garrigues
Award Amount: $143,986.00
Abstract:
Not Available Advances in sensor technology have significantly expanded the potential role of multi- and hyperspectral imaging in a wide range of military scenarios. However, for these advances to be of use of human interpreters, image display technologies must be developed requiring new image… More

AMYLOID INHIBITING AGENT FOR ALZHEIMERS DISEASE

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gerardo M. Castillo
Award Amount: $227,501.00
Abstract:
Not Available MCE will investigate the possibility of using multiple collectors and detectors to develop a DIMM that is both portable and capable of obtaining atmospheric turbulence data from stellar sources and laser sources during nighttime and daytime hours. The proposers have many years… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gerardo M. Castillo
Award Amount: $197,006.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan D. Snow
Award Amount: $272,398.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gerardo M. Castillo
Award Amount: $249,401.00

Amyloid Inhibiting Agent for Treatment of Alzheimer's

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gerardo M. Castillo
Award Amount: $0.00
Abstract:
Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profound mental deterioration and ultimately death. AD is the leading cause of dementia in the elderly,… More

Amyloid Inhibiting Agent for Treatment of Alzheimer's

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Gerardo M. Castillo
Award Amount: $789,141.00
Abstract:
Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profound mental deterioration and ultimately death. AD is the leading cause of dementia in the elderly,… More

Alzheimer's Amyloid Plaque Persistence In Vivo

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan D. Snow
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately… More

Alzheimer's Amyloid Plaque Persistence In Vivo

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alan D. Snow
Award Amount: $485,177.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately… More

INHIBITORS OF ALZHEIMER'S DISEASE AMYLOIDOSIS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gerardo M. Castillo
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately death. AD is the leading… More

Proteoglycans/Glycosaminoglycans in APP Transgenic Mice

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan D. Snow
Award Amount: $520,841.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorders characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately death. AD is the leading… More

Systemic AA Amyloidosis Inhibitors

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan D. Snow
Award Amount: $264,984.00
Abstract:
DESCRIPTION (provided by applicant): Systemic AA amyloidosis is characterized by the deposition and accumulation of insoluble fibrillar deposits containing the AA amyloid protein in a number of different organs (including heart, kidney, spleen, lungs and/or gastrointestinal tract), whereby such… More

Laminin-Derived Protein Fragments as Inhibitors of Alzheimer's Amyloidosis

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alan D. Snow
Award Amount: $2,288,173.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, and judgment that gradually leads to profound mental deterioration and ultimately death. AD is the leading cause of dementia in… More

Systemic AA Amyloidosis Inhibitors

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,330,463.00
Abstract:
DESCRIPTION (provided by applicant): Systemic AA Amyloidosis is characterized by the accumulation of insoluble fibril deposits containing the AA amyloid protein in different organs throughout the body including heart, kidney, liver, spleen, lungs, skin and gastrointestinal tract, whereby such… More

Identification of Novel Small Molecules as Tau Protein Aggregation Inhibitors for

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alan D. Snow – 425-823-6364
Award Amount: $770,675.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid (A2) and tau protein containing neurofibrillary tangles (NFTs). AD drug discovery strategies have been largelyfocused on reducing brain A2 levels,… More

Tau Protein Aggregation Inhibitors for Tauopathies

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Alan D. Snow – 425-823-6364
Award Amount: $2,271,931.00
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid protein (A?), and neurofibrillary tangles (NFTs) containing aggregated tau protein. AD drug discovery efforts havebeen largely focused on reducing brain… More